New Amgen Drug MariTide Shows Promising Weight Loss in Early Data

Published On Nov 26, 2024, 10:11 AM

Amgen announced promising results for its experimental obesity drug, MariTide, which helped patients lose an average of up to 20% of their weight over a year. The drug, delivered via a monthly injection, is still in early clinical trial stages and years away from market release. The trial involved nearly 600 participants, and results suggested the possibility of maintaining weight loss post-treatment. However, some side effects like nausea and vomiting were reported. MariTide's unique mechanism differentiates it from existing obesity drugs like Wegovy and Mounjaro, potentially positioning it favorably in a competitive market.